Coverage
-
October 17, 2025
A New Jersey federal judge trimmed claims in a proposed class action accusing animal-health giant Zoetis Inc. of concealing safety risks tied to its canine arthritis drug Librela, finding that the pet owners failed to allege specific misrepresentations or viable product-defect theories.
1 other articles on this case.
View all »